<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2192">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132621</url>
  </required_header>
  <id_info>
    <org_study_id>SLEIGA-1</org_study_id>
    <nct_id>NCT05132621</nct_id>
  </id_info>
  <brief_title>The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.</brief_title>
  <official_title>The Genital Tract Microflora in Women With Systemic Lupus Erythematosus and IgA Nephropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis:&#xD;
&#xD;
      Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of&#xD;
      clinical manifestations. Its mechanisms are not well understood. It is known that its&#xD;
      development is influenced by genetic factors and gender. However, it is believed that in some&#xD;
      patients with a specific genetic predisposition, certain environmental factors such as&#xD;
      chemicals, including drugs and toxins, smoking, or infections may initiate the development of&#xD;
      the disease. Of particular importance seem to be infections, which by stimulating the immune&#xD;
      system can induce new symptoms or exacerbate existing ones.&#xD;
&#xD;
      For this reason, links between the microbiome and the clinical course of SLE are being&#xD;
      sought. Most available studies concern the intestinal microbiome. So far, the relationship&#xD;
      between the genital tract microbiota and the clinical picture of SLE has not been documented.&#xD;
&#xD;
      Aim of the study:&#xD;
&#xD;
      This study aims to identify and differentiate the genital tract microbiota of women with a&#xD;
      diagnosis of systemic lupus, IgA nephropathy and a control group of healthy women. The&#xD;
      results will be correlated with the clinical presentation of these diseases. In addition, the&#xD;
      isolated bacterial strains will be secured for further study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in microflora composition between groups of study participants</measure>
    <time_frame>Two months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Immunoglobulin A Nephropathy</condition>
  <arm_group>
    <arm_group_label>Participants diagnosed with SLE</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants diagnosed with IgA nephropathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Participants</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Smear</intervention_name>
    <description>A smear of the posterior vaginal fornix collected with a gynecological speculum.</description>
    <arm_group_label>Healthy Participants</arm_group_label>
    <arm_group_label>Participants diagnosed with IgA nephropathy</arm_group_label>
    <arm_group_label>Participants diagnosed with SLE</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Vaginal secretion&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50 participants diagnosed with SLE and 50 participants diagnosed with IgA nephropathy will&#xD;
        be included in the study. The control group will consist of 50 healthy participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years,&#xD;
&#xD;
          -  Confirmed diagnosis of SLE or IgA nephropathy,&#xD;
&#xD;
          -  First half of the menstrual cycle, after the end of bleeding,&#xD;
&#xD;
          -  Signed informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of menstruation,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Active infection requiring parenteral or topical antibiotic therapy within 2 weeks&#xD;
             before examination,&#xD;
&#xD;
          -  Neoplastic disease of the reproductive tract.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>A study based on the analysis of genital tract microflora of women of reproductive age.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Dept. of Immunology, Transplantology and Internal Medicine Transplantation Institute, Warsaw Medical University</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiome</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>IgA nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

